MedPath

Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment

Phase 3
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: MGN1703 treatment
Other: Usual Maintenance
Registration Number
NCT02077868
Lead Sponsor
Mologen AG
Brief Summary

The purpose of this this trial is to prove the efficacy and safety of MGN1703 as a maintenance therapy after first-line chemotherapeutic treatment of metastatic colorectal cancer.

Detailed Description

Due to the toxicity of chemotherapeutic medications treatment breaks are common practice in the treatment of metastatic colorectal cancer. During these treatment breaks a variety of maintenance treatments are available.

MGN1703 is developed not only to help the Patient to recover from chemotherapy but also to boost the patient's immune System and thus help him to effectively fight the Tumor himself.

After the concept has already been proved in a previous study this Trial is conducted to further evaluate the safety and efficacy of MGN1703 Treatment.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
540
Inclusion Criteria
  • Signed written informed consent
  • Male or female patient 18 years or older
  • Histologically confirmed diagnosis of colorectal cancer presenting with unresectable stage IV (UICC) disease (primary tumor may be present)
  • Complete or partial response, as assessed by local investigators according to RECIST 1.1, within 12-30 weeks from start of induction treatment with standard first-line chemotherapy with or without biological agents
  • ECOG PS 0-1
  • Haematology and biochemistry laboratory results within the limits normally expected for the patient population recovering after receiving induction treatment
  • Male and female patients of childbearing potential (i.e. did not undergo surgical sterilization - hysterectomy, bilateral tubal ligation, or bilateral oophorectomy - and are not post-menopausal for at least 24 consecutive months) must use an effective method of contraception. Females of child bearing potential must have a negative serum pregnancy test
Exclusion Criteria
  • History of other malignant tumors within the last 5 years, except basal cell carcinoma or curatively excised cervical carcinoma in situ
  • Known brain metastases (present or treated)
  • Contraindication to receiving MGN1703 as per current investigator brochure
  • Known hypersensitivity to any component of the study product
  • Prior allogeneic stem cell transplantation or organ transplantation
  • Active or uncontrolled infections or undiagnosed febrile condition
  • Severe anemia requiring repeated blood cell transfusion
  • Pre-existing autoimmune or antibody-mediated diseases or immune deficiency
  • Chronic systemic immune therapy or immunosuppressant medication other than steroids within the last 6 weeks; continuous systemic steroid treatment within the last 2 weeks prior to start of study treatment
  • Use of systemic antibiotic therapy within the last 2 weeks prior to start of study treatment
  • Inadequate pulmonary function according to the Investigator's judgment, history of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
  • HIV seropositivity or active HBV/HCV infection
  • Serious concomitant disease or medical condition that in the judgment of the investigator renders the patient at high risk of treatment complications
  • Female patient who is pregnant or breast feeding
  • Contraindication to receive the planned standard maintenance treatment according to applicable SmPC
  • Treatment with any anti-cancer investigational drug within 12 months prior to study treatment or participation in another clinical study with other investigational drugs within 28 days prior to study treatment
  • Vaccination within 1 months prior to start of study treatment
  • Any medical, mental, psychological or psychiatric condition that in the opinion of the investigator would not permit the patient to complete the study or understand the patient information

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Treatment Arm BMGN1703 treatmentMGN1703 treatment as maintenance therapy
Control Arm AUsual MaintenancePatients in Control Arm A receive usual maintenance Treatment according to local investigator's decsision
Primary Outcome Measures
NameTimeMethod
Overall survival36 months

Overall survival after randomization

Secondary Outcome Measures
NameTimeMethod
Progression Free Survival (PFS)36 months

PFS1: from randomization until first PD PFS2: from start of re-introduction therapy until second PD PFS3: from start of first-line Treatment until second PD

Safety36 months

AEs, vital signs, ECGs, safety labs as required

Overall Response rate36 months

Complete and partial responses according RECIST 1.1 after randomization

Quality of life (QoL)36 months

QoL according EORTC questionnaires

Trial Locations

Locations (121)

Krankenhaus Hietzing

🇦🇹

Vienna, Austria

Universitätsklinik Wien

🇦🇹

Vienna, Austria

UZ Leuven

🇧🇪

Leuven, Belgium

Kaiser-Franz-Josef-Spital

🇦🇹

Vienna, Austria

Onze-Lieve-Vrouwziekenhuis VZW (OLV)

🇧🇪

Aalst, Belgium

Hôpital Jean Minjoz

🇫🇷

Besançon, France

North Estonia Medical Centre

🇪🇪

Tallinn, Estonia

Hôpital Henri Mondor

🇫🇷

Créteil, France

Centre Hospitalier Privé Saint-Grégoire

🇫🇷

Saint-Gregoire, France

Centre Eugene Marquis

🇫🇷

Rennes, France

Medizinisches Versorgungszentrum Ärzteforum Seestrasse

🇩🇪

Berlin, Germany

Gefos Dortmund MBM

🇩🇪

Dortmund, Germany

Unversitätsklinikum Carl Gustav Carus

🇩🇪

Dresden, Germany

Medizinisches Versorgungszentrum Osthessen GmbH

🇩🇪

Fulda, Germany

Frankfurter Diakonie Kliniken

🇩🇪

Frankfurt, Germany

Universitätsklinikum Frankfurt

🇩🇪

Frankfurt, Germany

Klinik für Tumorbiologie

🇩🇪

Freiburg, Germany

Universitätsklinikum Freiburg

🇩🇪

Freiburg, Germany

Medizinische Hochschule Hannover

🇩🇪

Hannover, Germany

Kliniken Maria Hilf GmbH

🇩🇪

Mönchengladbach, Germany

Sana Kliniken Ostholstein

🇩🇪

Oldenburg, Germany

St. Vincenz-Krankenhaus

🇩🇪

Paderborn, Germany

Horst Schmidt Klinik

🇩🇪

Wiesbaden, Germany

Marienhospital

🇩🇪

Witten, Germany

Universitätsklinikum Halle (Saale)

🇩🇪

Halle, Germany

Facharztzentrum Eppendorf

🇩🇪

Hamburg, Germany

Onkologie Dreiländerdreieck

🇩🇪

Lörrach, Germany

Onkologie Dreiländereck - Onkologische Schwerpunktpraxis Lörrach

🇩🇪

Lörrach, Germany

Klinikum Nürnberg

🇩🇪

Nürnberg, Germany

Pius-Hospital Oldenburg

🇩🇪

Oldenburg, Germany

Klinikum rechts der Isar

🇩🇪

München, Germany

Klinikum Oldenburg

🇩🇪

Oldenburg, Germany

Oncologianova GmbH

🇩🇪

Recklinghausen, Germany

Paracelsus-Krankenhaus Ruit

🇩🇪

Ostfildern, Germany

Universitätsklinikum Tübingen

🇩🇪

Tübingen, Germany

Azienda Ospedaliero-Universitaria Santa Maria della Misericordia

🇮🇹

Udine, Italy

Landesklinikum Krems

🇦🇹

Krems, Austria

Antwerp University Hospital

🇧🇪

Edegem, Belgium

East-Tallinn Central Hospital

🇪🇪

Tallinn, Estonia

University clinic Tartu

🇪🇪

Tartu, Estonia

CHRU Brest - Hôpital Morvan

🇫🇷

Brest, France

Institut Bergonié

🇫🇷

Bordeaux, France

Polyclinique du Bois

🇫🇷

La Chaussée Saint Victor, France

Centre Hospitalier Belfort-Montbéliard

🇫🇷

Montbeliard, France

Centre Hospitalier Départemental Vendée

🇫🇷

La Roche sur Yon, France

Clinique Victor Hugo

🇫🇷

Le Mans, France

Hôpital Antoine-Béclère

🇫🇷

Paris, France

Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez

🇫🇷

Lille, France

CHU Hôpital de la Timone

🇫🇷

Marseille, France

Groupe Hosptalier Paris Saint Joseph

🇫🇷

Paris, France

Institut Mutualiste Montsouris

🇫🇷

Paris, France

Hôpital Européen Georges Pompidou (HEGP)

🇫🇷

Paris, France

Hopital Pitie-Salpetriere

🇫🇷

Paris, France

CHU de Poitiers

🇫🇷

Poitiers, France

Clinique Saint Anne, Strasbourg Oncologie Liberale

🇫🇷

Strasbourg, France

Gustave Roussy Cancer Campus

🇫🇷

Paris, France

Internistische Schwerpunktpraxis

🇩🇪

Bad Reichenhall, Germany

Zentralklinik Bad Berka GmbH

🇩🇪

Bad Berka, Germany

Klinikum Augsburg

🇩🇪

Augsburg, Germany

Hôpital Rangueil

🇫🇷

Toulouse, France

Klinikum Mittelbaden Baden-Baden Balg

🇩🇪

Baden Baden, Germany

Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin

🇩🇪

Berlin, Germany

Klinikum Bayreuth GmbH

🇩🇪

Bayreuth, Germany

Klinikum Mittelbaden Medizinische Klinik II

🇩🇪

Baden-Baden, Germany

Onkologie / Hämatologie

🇩🇪

Bottrop, Germany

Ärzteforum Hennigsdorf

🇩🇪

Berlin, Germany

Überörtliche Gemeinschaftspraxis

🇩🇪

Bottrop, Germany

St. Josef-Hospital im Katholischen Klinikum Bochum

🇩🇪

Bochum, Germany

DIAKO Ev. Diakonie-Krankenhaus gemeinnützige GmbH

🇩🇪

Bremen, Germany

Onkozentrum Dresden/Freiberg

🇩🇪

Dresden, Germany

Kliniken Essen-Mitte

🇩🇪

Essen, Germany

Universitätsklinikum Gießen und Marburg, Standort Gießen

🇩🇪

Gießen, Germany

Onkologische Schwerpunktpraxis

🇩🇪

Gütersloh, Germany

MVZ Onkologische Kooperation Harz

🇩🇪

Goslar, Germany

Universitätsklinikum Köln

🇩🇪

Köln, Germany

Onkologische Schwerpunktpraxis Leer-Emden

🇩🇪

Leer, Germany

Klinikum Leverkusen

🇩🇪

Leverkusen, Germany

Klinikum Ludwigsburg

🇩🇪

Ludwigsburg, Germany

Universitaetsmedizin der Johannes-Gutenberg-Universitaet

🇩🇪

Mainz, Germany

Klinikum Mannheim GmbH

🇩🇪

Mannheim, Germany

Klinikum Neuperlach

🇩🇪

München, Germany

University Hospital Marburg

🇩🇪

Marburg, Germany

Klinikum Bogenhausen

🇩🇪

München, Germany

Elblandkliniken

🇩🇪

Riesa, Germany

Klinikum Stuttgart - Katharinenhospital

🇩🇪

Stuttgard, Germany

Vivantes Klinikum

🇩🇪

Spandau, Germany

HELIOS Klinikum Wuppertal Medizinische Klinik I

🇩🇪

Wuppertal, Germany

Kliniken Südostbayern

🇩🇪

Traunstein, Germany

Universitätsklinikum Ulm

🇩🇪

Ulm, Germany

Candiolo Cancer Institute

🇮🇹

Candiolo, Italy

Azienda Ospedaliero-Universitaria Careggi

🇮🇹

Firenze, Italy

University Hospital San Martino

🇮🇹

Genova, Italy

Ospedale San Raffaele

🇮🇹

Milano, Italy

Policlinico San Mateo

🇮🇹

Pavia, Italy

Istituto Oncologico Veneto

🇮🇹

Padova, Italy

Ospedale Infermi di Rimini, U.O. Oncologia

🇮🇹

Rimini, Italy

Ospedale Civile SS Annunziata, U.O.C. Oncologia Medica

🇮🇹

Sassari, Italy

Hospital Clinic

🇪🇸

Barcelona, Spain

Hospital de la Santa Creu i Sant Pau

🇪🇸

Hospitalet de Llobregat, Spain

Hospital Universitari Germans Trias i Pujol

🇪🇸

Barcelona, Spain

Hospital Universitario Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital Reina Sofía

🇪🇸

Cordoba, Spain

Parc Tauli Sabadell Hospital

🇪🇸

Barcelona, Spain

Hospital Clínico San Carlos

🇪🇸

Madrid, Spain

Hospital General Universitario Gregorio Marañón

🇪🇸

Madrid, Spain

Hospital Universitario 12 de Octubre

🇪🇸

Santander, Spain

Hospital Universitario Ramon y Cajal

🇪🇸

Madrid, Spain

Hospital Universitario Puerta de Hierro - Majadahonda

🇪🇸

Madrid, Spain

Hospital Regional Universitario Carlos Haya

🇪🇸

Malaga, Spain

Hospital Universitario Central de Asturias

🇪🇸

Oviedo, Spain

Hospital Son Llatzer

🇪🇸

Palma de Mallorca, Spain

Complejo Hospitalario Universitario

🇪🇸

Santiago de Compostela, Spain

Aberdeen Royal Infirmary

🇬🇧

Aberdeen, United Kingdom

Consorcio Hospital General de Valencia

🇪🇸

Valencia, Spain

The Christie Clinic

🇬🇧

Manchester, United Kingdom

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust - Royal Bournemouth Hospital

🇬🇧

Bournemouth, United Kingdom

Royal Marsden Hospital

🇬🇧

Sutton, United Kingdom

Oxford University Hospitals NHS Trust - Churchill Hospital

🇬🇧

Oxford, United Kingdom

York Teaching Hospitals NHS Fondation Trust, Research and Development department

🇬🇧

York, United Kingdom

Complexo Hospitalario Universitario A Coruña

🇪🇸

La Coruna, Spain

Hospital Universitario Arnau de Vilanova

🇪🇸

Lleida, Spain

© Copyright 2025. All Rights Reserved by MedPath